Published in J Pharmacogenomics Pharmacoproteomics on March 27, 2013
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One (2016) 0.78
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metabol Personal Ther (2015) 0.78
Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metabol Personal Ther (2015) 0.75
Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics (2016) 0.75
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 3.92
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol (2007) 2.71
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res (2007) 2.20
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol (2000) 1.51
SPSmart: adapting population based SNP genotype databases for fast and comprehensive web access. BMC Bioinformatics (2008) 1.51
Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther (1989) 1.48
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol (1990) 1.37
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics (1999) 1.36
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist (2006) 1.30
Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics (2009) 1.11
The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics. J Pharmacogenomics Pharmacoproteomics (2010) 1.02
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics (1996) 0.99
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther (2000) 0.96
Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin Psychiatry (2007) 0.81
Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J (2008) 0.80
The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact (2000) 0.78
'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics (2012) 0.77
Redundant or separate entities?--roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res (2010) 1.35
Factors controlling the reactivity of hydrogen sulfide with hemeproteins. Biochemistry (2009) 1.18
Homozygous nonsense mutations in TWIST2 cause Setleis syndrome. Am J Hum Genet (2010) 1.15
Genetic testing for oculocutaneous albinism type 1 and 2 and Hermansky-Pudlak syndrome type 1 and 3 mutations in Puerto Rico. J Invest Dermatol (2006) 1.12
Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics (2009) 1.11
High-level production of recombinant sulfide-reactive hemoglobin I from Lucina pectinata in Escherichia coli. High yields of fully functional holoprotein synthesis in the BLi5 E. coli strain. Protein Expr Purif (2004) 1.00
CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med (2013) 0.98
The cDNA-derived amino acid sequence of hemoglobin II from Lucina pectinata. J Protein Chem (2003) 0.98
MTHFR polymorphisms in Puerto Rican children with isolated congenital heart disease and their mothers. Int J Genet Mol Biol (2010) 0.96
Tyrosine B10 and heme-ligand interactions of Lucina pectinata hemoglobin II: control of heme reactivity. Biochim Biophys Acta (2004) 0.96
Structure and ligand selection of hemoglobin II from Lucina pectinata. J Biol Chem (2008) 0.94
CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta (2010) 0.93
Prevalence of a loss-of-function mutation in the proton-coupled folate transporter gene (PCFT-SLC46A1) causing hereditary folate malabsorption in Puerto Rico. J Pediatr (2011) 0.93
Hemoglobin I from Lucina pectinata: a model for distal heme-ligand control. Biochim Biophys Acta (2005) 0.91
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother (2012) 0.87
A divalent interaction between HPS1 and HPS4 is required for the formation of the biogenesis of lysosome-related organelle complex-3 (BLOC-3). Biochim Biophys Acta (2012) 0.87
Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85
Nonsense mutations of the bHLH transcription factor TWIST2 found in Setleis Syndrome patients cause dysregulation of periostin. Int J Biochem Cell Biol (2011) 0.84
Hydrogen-bonding conformations of tyrosine B10 tailor the hemeprotein reactivity of ferryl species. J Biol Inorg Chem (2006) 0.84
Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis. PLoS One (2012) 0.84
The bio-energetic theory of carcinogenesis. Med Hypotheses (2012) 0.83
Newborn screening for hermansky-pudlak syndrome type 3 in Puerto Rico. J Pediatr Hematol Oncol (2010) 0.83
Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J (2015) 0.81
Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis (2009) 0.81
[Differences in the stress symptoms rating scale in Spanish between patients with irritable bowel syndrome (IBS) and healthy controls]. Rev Gastroenterol Mex (2003) 0.81
Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother (2007) 0.80
Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J (2008) 0.80
Functional characterization of the purified holo form of hemoglobin I from Lucina pectinata overexpressed in Escherichia coli. Protein J (2004) 0.79
Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics (2012) 0.79
Recombinant hemoglobin II from Lucina pectinata: a large-scale method for hemeprotein expression in E. coli. Protein J (2010) 0.79
Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. J Orthomol Med (2010) 0.79
Characterization of the full length mRNA coding for Lucina pectinata HbIII revealed an alternative polyadenylation site. Gene (2008) 0.79
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metabol Personal Ther (2015) 0.78
Biodistribution of liposome-entrapped human gamma-globulin. Biopharm Drug Dispos (2006) 0.78
Poor response to desmopressin acetate (DDAVP) in children with Hermansky-Pudlak syndrome. Pediatr Blood Cancer (2005) 0.77
Presence of the 5,10-methylenetetrahydrofolate reductase C677T mutation in Puerto Rican patients with neural tube defects. J Child Neurol (2002) 0.77
'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics (2012) 0.77
Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med (2008) 0.77
Hemostatic matrix application after open synovectomy in a hemophilic patient. Am J Orthop (Belle Mead NJ) (2012) 0.77
Metabolic Correction as a tool to improve diabetes type 2 management. Bol Asoc Med P R (2015) 0.76
Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J (2014) 0.76
Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background. P R Health Sci J (2015) 0.76
Metabolic correction: a functional biochemical mechanism against disease--Part 2: mechanisms and benefits. P R Health Sci J (2015) 0.76
Molecular Cloning and Characterization of a (Lys)6-Tagged Sulfide-Reactive Hemoglobin I from Lucina pectinata. Mol Biotechnol (2015) 0.75
Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metabol Personal Ther (2017) 0.75
Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later: comment on the article by Cabanillas. P R Health Sci J (2010) 0.75
Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metabol Personal Ther (2015) 0.75
Correction: Evolution of the Twist Subfamily Vertebrate Proteins: Discovery of a Signature Motif and Origin of the Twist1 Glycine-Rich Motifs in the Amino-Terminus Disordered Domain. PLoS One (2016) 0.75
Asymptomatic child heterozygous for hemoglobin S and hemoglobin Pôrto Alegre. Pediatr Blood Cancer (2010) 0.75
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J (2010) 0.75
For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethn Dis (2009) 0.75
Severe neutropenia in an infant with methylmalonic acidemia. Bol Asoc Med P R (2003) 0.75
First case of dizygotic twins with lamellar ichthyosis in Puerto Rico. Bol Asoc Med P R (2012) 0.75
[Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R (2015) 0.75
Erythrocyte volume, folate levels, and the presence of methylenetetrahydrofolate reductase polymorphism. P R Health Sci J (2002) 0.75